Differential Molecular Expression Patterns Associated with Metastasis in Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Mulvaney, Patrick M.; Massey, Paul R.; Yu, Kenneth K.; Drinan, J.; Schmults, C.

doi:10.1016/j.jid.2021.02.741

Cited by 9 publications

(8 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Expression of individual tumor markers is prognostic in cSCC. Tumor expression of programmed death-1 ligand (PD-L1) carries increased risk of nodal metastasis according to a meta-analysis of seven studies (odds ratio 2.34) [ 41 ]. Additional tumor markers associated with local recurrence, perineural invasion (PNI), metastasis, and poor survival include inositol polyphosphate 5-phosphatase, p300, telomerase reverse transcriptase, CD133, thymidine kinase 1, Myb-related protein B, and long noncoding RNAs [ 42 , 43 , 44 , 45 , 46 , 47 ].…”

Section: Determining High-risk Cscc and Prognostic Indicatorsmentioning

confidence: 99%

Advances in Cutaneous Squamous Cell Carcinoma Management

Burns

Kubicki

Nguyen

et al. 2022

Cancers

View full text Add to dashboard Cite

cSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. This review presents significant changes in the management of cSCC, focusing on improvements in risk stratification, new treatment options, optimization of existing treatments, and prevention strategies. One major breakthrough in cSCC treatment is the advent of immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), which have ushered in a renaissance in the treatment of patients with locally advanced and metastatic disease. These agents have offered patients with advanced disease decreased therapeutic toxicity compared to traditional chemotherapy agents, a more durable response after discontinuation, and improved survival. cSCC is an active field of research, and this review will highlight some of the novel and more developed clinical trials that are likely to impact cSCC management in the near future.

show abstract

Section: Determining High-risk Cscc and Prognostic Indicatorsmentioning

confidence: 99%

Advances in Cutaneous Squamous Cell Carcinoma Management

Burns

Kubicki

Nguyen

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…This could contribute to a better prediction of the occurrence of pulmonary metastasis (J. Wang et al, 2020). In skin squamous cell carcinoma, increased expression of PD‐L1 encoding RNA in the primary tumor increased the risk of metastasis (Mulvaney et al, 2021). However, a meta‐analysis in patients with melanoma concluded that PD‐L1 was not associated with poor prognosis, and increased PD‐L1 expression was related to the lack of lymph node metastasis (J. Yang et al, 2020).…”

Section: Exosomal Pd‐l1 As Diagnostic and Prognostic Markers In Cancersmentioning

confidence: 99%

Tumor‐derived exosomal PD‐L1 in progression of cancer and immunotherapy

Rasihashemi

Rezazadeh-Gavgani

Majidazar

et al. 2021

Journal Cellular Physiology

View full text Add to dashboard Cite

Cancer is a gravely important health issue all over the world and has been spreading fast. In recent years immune checkpoint treatment options have been used extensively as a primary line of treatment for different cancer types. PD‐1 and its ligand, PD‐L1, are members of the immune‐checkpoints superfamily. Anti‐PD‐L1 and anti‐PD‐1 antibodies have shown efficacy against different cancer types, but fewer than 30% of patients have shown robust therapeutic responses and, therefore, it is hypothesized that exosomal PD‐L1 is the mechanism to blame for failure in primary immune checkpoint therapy. The identical membrane topology of exosomal PD‐L1 with tumor cell membrane‐type provides the possibility to mimic immunosuppressive effects of tumor cell membrane PD‐L1. In this review, it is discussed whether exosomal PD‐L1 binds to antibodies and hence resistance to immunotherapy will be developed, and targeting exosome biogenesis inhibition can provide a new strategy to overcome tumor resistance to anti‐PD‐L1 therapy. Diagnostic and prognostic values of exosomal PD‐L1 in different cancer types are discussed. Multiple clinical studies conclude that the level of tumor‐derived exosomes (TEXs) as a biomarker for diagnosis could distinguish cancer patients from healthy controls. Elevated exosomal PD‐L1 levels may be predictive of advanced disease stages, cancer metastasis, lower response to anti‐PD‐1/PD‐L1 therapy, lower overall survival rates, and poor tumor prognosis. These novel findings of TEXs serve as promising therapeutic targets for early diagnosis and prevention of cancer progression.

show abstract

“…Hooghiemstra, 4 Jan J. Doff, 2 Gilles F.H. Diercks, 2 Gooitzen M. van Dam, 5,6 Max J.H. Witjes 1 and Sebastiaan A.H.J.…”

unclassified

“… 3 , 4 A common target for FMI is epidermal growth factor receptor (EGFR), a transmembrane receptor overexpressed in up to 90% of cSSCs. 5 …”

mentioning

confidence: 99%

“…3,4 A common target for FMI is epidermal growth factor receptor (EGFR), a transmembrane receptor overexpressed in up to 90% of cSSCs. 5 In this proof-of-concept study, we explored the potential of FMI using cetuximab-800CW for discrimination between cSCC and adjacent tissue. Ten patients were included with histology-confirmed cSCC, scheduled for conventional excision or MMS.…”

mentioning

confidence: 99%

See 1 more Smart Citation